The Prognosis For Personalis

Jun. 16, 2022 12:41 PM ETPersonalis, Inc. (PSNL)ILMN, ARKG, EDOC, WDNA, IDNA, ETEC, IWC, BBQ, BIB, BBSC, VTWV2 Likes


  • Today, we profile Personalis, a small cancer genomics testing firm.
  • The stock has taken a battering in 2022 and is posting substantial quarterly losses, but shares now sell for less than net cash.
  • 2022 is a transition year for the company in many ways. An investment analysis follows in the paragraphs below.
  • Looking for a portfolio of ideas like this one? Members of The Biotech Forum get exclusive access to our model portfolio. Learn More »

Dividing Cancer Cell Oncology Research Concept 3d illustration proteins with lymphocytes gene editing , t cells or cancer cells, meiosis, mitosis

CIPhotos/iStock via Getty Images

There should be an honored place in history for statesmen whose ideas turned out to be right.”― Walter Isaacson

Today, we put Personalis, Inc. (NASDAQ:PSNL) in the spotlight here at the Biotech Forum for the first time. The stock of this small cancer genomics concern have cratered over the past year. The company is posting some large losses, but the stock's market cap is currently significantly below the net cash on its balance sheet. Oversold or a value trap? An analysis follows below.

PSNL Stock Chart

Seeking Alpha

Company Overview

Personalis is headquartered just outside of San Francisco. The company is focused on enabling the next generation of precision cancer therapies and diagnostics. Its Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. The company was founded by executives from industry heavyweight Illumina (ILMN). The stock currently trades just under $3.50 a share and sports an approximate market capitalization of $180 million.

Personalis Company Overview

April Company Presentation

The company has several approved tests on the market. Personalis has garnered a large portion of its revenues since coming public via a contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). That revenue stream is shrinking and being de-emphasized as the company focuses on growing its oncology testing business via its NeXT platform.

Product Portfolio

April Company Presentation

First Quarter Results

On May 4th, the company posted its first quarter results. Personalis posted a GAAP net loss of 63 cents a share, slight below expectations. Revenues fell some 27% on a year-over-year basis to just over $15 million, a tad over the analyst consensus.

VA MVP revenue for the quarter came in at $3.5 million. This was expected but was 73% lower than 1Q2021., compared with $13.2 million for the same period of the prior year. Management did state that unfulfilled orders from this contract were $4.1 million at the end of the first quarter and they expect the unfulfilled orders to convert to revenue during the second quarter.

Cancer Trends

April Company Presentation

The company's oncology focus is resulting in good growth, albeit off a fairly low base. Biopharma and all other customers accounted for revenue of $11.7 million in the first quarter, up more than 50% from the same period of a year ago. This was driven by the continued adoption of the company's NeXT Platform, which accounted for nearly two-thirds of this revenue during the quarter.

For the full year, management expects $62 million to $67 million in overall revenue. Of which, oncology revenue from biopharma and other customers to be in the range of $55 million to $60 million.

Key Clinical Studies

April Company Presentation

Leadership also mentioned its business continues to be impacted by the lingering impacts of the pandemic. One of the key long term growth drivers for the company is partnering with oncology firms during trials. In fact, half of Personalis' biopharma work is now for these prospective clinical trial projects. Covid-19 continues to delay and reduce patient enrollment in these studies. The company's effort to expand its footprint in China has also suffered due to the lockdowns in Shanghai where its lab is as well.

Analyst Commentary & Balance Sheet

Since first quarter numbers were posted, Morgan Stanley ($13 price target) and Needham have reiterated Hold ratings on the stock. Both BTIG ($15 price target) and H.C. Wainwright ($30 price target) have reissued Buy ratings. Citigroup did the same but lowered its price target to $14 from $18 a share previously.

Approximately five percent of the outstanding shares are currently sold short. A beneficial owner added just over $3 million to their holdings in early March. Since then, four insiders have made very small sales. The company ended the fourth quarter with just over $265 million of cash and marketable securities on its balance sheet after posting a net loss of $28.2 million during the quarter. The company has negligible long term debt, but has access to credit facilities if needed. The company used just over $20 million of cash during the first quarter. Leadership projects it will burn through approximately $140 million for all of FY2022. This includes a one-time investment of approximately $45 million for the construction and fit-up of a new company facility, which is one of the company's key initiatives.

Key Initiatives

April Company Presentation


The current analyst consensus has the company losing $2.50 a share in FY2022 as revenues fall some 25% to some $64 million. Revenues should stabilize near FY2020's levels of $85 million according to analysts in FY2023, even as losses are projected to come in around this fiscal year's levels.

Potential Markets

April Company Presentation

There is no doubt that Personalis is aiming at some very large potential markets. 2022 is going to be a transition year as the company's VA MVP business continues to ebb and as its builds up its oncology business while building out capacity at a new facility. Growth will return in FY2023 and beyond, and the company appears to have enough cash to bridge that transition.

The market has been absolutely brutal to profitless small cap concerns in 2022, knocking many including Personalis to significantly under their net cash value. This puts no value on the company underlying assets and Personalis could easily be a strategic 'bolt on' acquisition for a larger player at current trading levels. However, that is probably the only way the shares have a sharp rebound until investing sentiment improves in the market.

We all have problems. Or rather, everyone has at least one thing that they regard as a problem.”― Mokokoma Mokhonoana

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

Bret Jensen profile picture
Finding tomorrow's big winners in the lucrative biotech sector

Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace Offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum


Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Bret Jensen is the Founder of and authors articles for the Biotech Forum, Busted IPO Forum and Insiders Forum.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.